<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334708</url>
  </required_header>
  <id_info>
    <org_study_id>17-527</org_study_id>
    <nct_id>NCT03334708</nct_id>
  </id_info>
  <brief_title>A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma</brief_title>
  <official_title>Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sha'are Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weizmann Institute of Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a minimally invasive test to diagnose pancreatic
      cancer at early stages of disease and monitor response to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Diseases</condition>
  <condition>Pancreatitis</condition>
  <condition>Pancreatic Cyst</condition>
  <arm_group>
    <arm_group_label>Locally Advanced or Metastatic Pancreatic Cancer Cohort</arm_group_label>
    <description>For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Benign Pancreatic Pathology Control Cohort</arm_group_label>
    <description>For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Benign Pancreatic Path,IPMC &amp; Pancreatic Cyst Ctrl</arm_group_label>
    <description>For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>For normal controls, blood specimens will be drawn once at study baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:
Patients and controls weighing 50kg or more
For draw amounts up to 50mL, there is no required hemoglobin threshold.
For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.
Patients and controls weighing &lt; 50kg
For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time.</description>
    <arm_group_label>Locally Advanced or Metastatic Pancreatic Cancer Cohort</arm_group_label>
    <arm_group_label>Acute Benign Pancreatic Pathology Control Cohort</arm_group_label>
    <arm_group_label>Chronic Benign Pancreatic Path,IPMC &amp; Pancreatic Cyst Ctrl</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tumor Tissue Collection</intervention_name>
    <description>Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere</description>
    <arm_group_label>Locally Advanced or Metastatic Pancreatic Cancer Cohort</arm_group_label>
    <arm_group_label>Acute Benign Pancreatic Pathology Control Cohort</arm_group_label>
    <arm_group_label>Chronic Benign Pancreatic Path,IPMC &amp; Pancreatic Cyst Ctrl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cyst Fluid</intervention_name>
    <description>Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere</description>
    <arm_group_label>Chronic Benign Pancreatic Path,IPMC &amp; Pancreatic Cyst Ctrl</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be analyzed for various biomarkers. Initial biomarkers to be tested
      include proteins and proteases, functional DNA repair assays, exosomes, stromal elements,
      circular RNAs (cRNA) and circulating tumor DNA (ctDNA).

      Tissue will be utilized from already planned. Biopsy tissue is expected to be available for
      virtually all PDAC patients, occasionally for IPMN and cysts patients, rarely for
      pancreatitis and never for healthy controls.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Potential research subjects in the PDAC and benign pancreatic disease cohorts will be
        identified by a member of the patient's treatment team, the principal investigator, or
        research team at participating institutions. If the investigator is a member of the
        treatment team, s/he will screen their patients' medical records for suitable research
        study participants and discuss the study and their potential for enrolling in the research
        study. The investigator will use information provided by the patient and/or medical record
        to confirm that the patient is eligible and contact the patient regarding study enrollment.
        Healthy controls will be recruited from patients from outpatient primary care clinics at
        non-MSK sites and volunteers from which may include the staffs members at collaborating
        sites.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Advanced Pancreatic Cancer Cohort Inclusion Criteria

          -  Histological or cytological confirmed diagnosis of locally advanced or metastatic
             pancreatic adenocarcinoma by the enrolling institution

          -  Patient planning to receive systemic treatment

          -  For stage IV patients, if adjuvant chemotherapy and/or chemoradiation therapy was
             received for AJCC Stage I-III pancreatic adenocarcinoma, patients are eligible if the
             last systemic therapy was given more than 6 months before initiation of currently
             planned systemic therapy

          -  Hemoglobin &gt; 8

          -  ECOG performance status 0-2

          -  A minimum age of 18 years old

          -  Willing to provide permission to obtain banked tumor tissue for analysis (previous
             biopsies or surgical material). New tumor biopsies are not required for entrance into
             the protocol.

        Acute Benign Pancreatic Pathology Control Inclusion Criteria

          -  Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the
             enrolling institution

          -  Hemoglobin &gt; 8

          -  ECOG performance status 0-2

          -  A minimum age of 18 years old

        Chronic Benign Pancreatic Pathology Control Inclusion Criteria

          -  Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic
             pathology by the enrolling institution

          -  Hemoglobin &gt; 8

          -  ECOG performance status 0-2

          -  A minimum age of 18 years old

        IPMN Control Inclusion Criteria

          -  Confirmed diagnosis of IPMN without high risk features by the enrolling institution

          -  Hemoglobin &gt; 8

          -  ECOG performance status 0-2

          -  A minimum age of 18 years old

        Pancreatic Cyst Control Inclusion Criteria

          -  Confirmed diagnosis of benign pancreatic cyst by the enrolling institution

          -  Hemoglobin &gt; 8

          -  ECOG performance status 0-2

          -  A minimum age of 18 years old

        Healthy Control Inclusion Criteria

          -  ECOG performance status 0-2

          -  A minimum age of 18 years old

        Exclusion Criteria:

        Advanced Pancreatic Cancer Cohort Exclusion Criteria

          -  Prior therapy for advanced/metastatic disease

          -  Adjuvant therapy for resected disease within the last 6 months

          -  Active second malignancy

          -  Any medical or psychiatric condition that may interfere with ability to comply with
             protocol procedures

        Acute Benign Pancreatic Pathology Control Exclusion Criteria

          -  Active or prior malignancy, except prior non-melanoma skin cancer

          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning
             for genetic predisposition to cancer

          -  Any medical or psychiatric condition that may interfere with ability to comply with
             protocol procedures

        Chronic Benign Pancreatic Pathology Control Exclusion Criteria

          -  Active or prior malignancy, except prior non-melanoma skin cancer

          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning
             for genetic predisposition to cancer

          -  Any medical or psychiatric condition that may interfere with ability to comply with
             protocol procedures

        IPMN Control Exclusion Criteria

          -  IPMN with high risk features or planned resection

          -  Active or prior malignancy, except prior non-melanoma skin cancer

          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning
             for genetic predisposition to cancer

          -  Any medical or psychiatric condition that may interfere with ability to comply with
             protocol procedures

        Pancreatic Cyst Control Exclusion Criteria

          -  Active or prior malignancy, except prior non-melanoma skin cancer

          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning
             for genetic predisposition to cancer

          -  Any medical or psychiatric condition that may interfere with ability to comply with
             protocol procedures

        Healthy Control Exclusion Criteria

          -  Active or prior malignancy, except prior non-melanoma skin cancer

          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning
             for genetic predisposition to cancer

          -  Any medical or psychiatric condition that may interfere with ability to comply with
             protocol procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kenneth Yu, MD</last_name>
    <phone>646-888-4188</phone>
    <email>yuk1@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Kelson, MD</last_name>
    <phone>646-888-4179</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Yu, MD</last_name>
      <phone>646-888-4188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Lyden, MD</last_name>
      <phone>212-746-6565</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sha'are Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ephrat Levy-Lahad, PhD</last_name>
      <phone>646-497-2600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weizmann Institute of Science</name>
      <address>
        <city>Reáº–ovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Avigdor Scherz, PhD</last_name>
      <phone>972 8-934-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Talia Golan, MD</last_name>
      <phone>03-5303295</phone>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>17-257</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatic Cyst</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

